Floatz logo

Elafibranor

Abdominal Obesity

GenfitSmall moleculePhase 2Dormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Abdominal Obesity cohort.

Asset / SponsorPhaseRating
Hydrochlorothiazide
UMC Utrecht
Phase 4BBB
Moxonidine
Baker Heart and Diabetes Institute
Phase 4BB
UMBELLATINE
China National Center for Cardiovascular Diseases
Phase 4BB
Irbesartan
Baker Heart and Diabetes Institute
Phase 4BB
Lisinopril
St. Paul Heart Clinic
Phase 3B

View all 27 →

Same molecule, other indications

Elafibranor is also rated in:

metabolic dysfunction-associated steatohepatitisDormant
BB
Indicative ·
66 / 100
View asset →
primary biliary cholangitisDormant
BB
Indicative ·
64 / 100
View asset →
primary sclerosing cholangitisDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →